Orion stock
ORNBV.HEHELOrion Oyj, HealthcareISIN FI0009014377
86Score 86 out of 100, Strong
Price and trend
77 / 100
Price history
+71% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 86).
The price is at its 52-week high. Largest decline in 20 years: 61% (June 2017 to July 2018).
Chart figures for advanced users
- SMA 50$97.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$84.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)86
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$65.49
- The lowest closing price of the last twelve months.
- Resistance$113.91
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Orion Oyj belongs to the Drug Manufacturers (General) industry (Finland) and, with a market value of $15.97B, is number 21 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.09B (up 22.5% year on year) and earnings of $554.38M (up 51.7%).
- For fiscal 2026, analysts expect on average revenue of $2.35B (up 12.1%) and adjusted earnings per share of $4.77 (up 20.9%).
Show more
- MEQIRI Score 86 out of 100 (Strong): rank 3 of 702 in Healthcare, median 53.
- The P/E is 22 (Drug Manufacturers (General) median 25.7, own median of recent years 22.2).
- Our model puts fair value at $135.33, with the price 16% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 39% in fiscal 2025, Drug Manufacturers (General) median 13.4%.Profitability 99
- High marginNet margin 30.3% over the last 12 months, Drug Manufacturers (General) median 17.5%.Profitability 99
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 87
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $104.10 and expensive above $193.33 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $137.37 (cash-flow model) and $133.29 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.6%. At 8.6% the fair value would be $123.00, at 6.6% it would be $153.91.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 33.7% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 64%, operating 33%, net 26%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 17 Feb 2027in 96 days
- Last reported
- 28 Oct 2026EPS reported $1.32 (expected $1.27)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 11.1% since 15 Oct 2026.
- Earnings per share
- $4.77+5.6%
- Revenue
- $2.35B+0.3%
- Earnings per share
- $5.98+11.1%
- Revenue
- $2.7B+1.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.3%Orion raised its full year outlook with net sales now guided at EUR 2.070 to 2.140 billion and operating profit at EUR 730 to 790 million, citing a strong first nine months, good Nubeqa royalties and a positive outlook for the rest of the year.
“And based on good first 9 months, very good royalties and good outlook for the rest of the year, we upgraded our financial outlook for this year so that our net sales range is from EUR 2.070 billion to EUR 2.140 billion. And our range for operating profit is from EUR 730 million to EUR 790 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at Orion
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 86
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Otsuka Holdings4578.T $40.24B78
- BiogenBIIB $37.03B60
- Daiichi Sankyo4568.T $32.6B73
- Astellas Pharma4503.T $30.07B87
- CSPC Pharmaceutical Group1093.HK $12.16B79
- Zhangzhou Pientzehuang Pharmaceutical.600436.SS $11.75B58
- GrifolsGRF.MC $8.79B66
- Ono Pharmaceutical4528.T $7.32B74
ETFs that hold Orion
Held by 128 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Franklin European Quality Dividend UCITS ETFFLXD | 4.21% | 0.25% | €684.01M |
| State Street SPDR S&P Euro Dividend Aristocrats UCITS ETF (Dist)SPYW | 2.13% | 0.30% | €1.88B |
| UBS Factor MSCI EMU Quality Screened UCITS ETF EUR disUIM2 | 1.60% | 0.25% | €105.49M |
Show 5 more
| iShares EURO STOXX Mid UCITS ETFIQQM | 1.34% | 0.40% | €560.15M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.22% | 0.40% | €1.5B |
| iShares MSCI EMU Mid Cap UCITS ETF EURIS3H | 0.96% | 0.49% | €570.32M |
| iShares STOXX Europe Equity Multifactor UCITS ETFIBC0 | 0.94% | 0.25% | €659.31M |
| Xtrackers MSCI Nordic UCITS ETF 1DXDN0 | 0.82% | 0.30% | €1.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Jan 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.